E
IMPL

Ergoteles’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Ergoteles’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,447
Closed -$119K – 2034
2022
Q3 		$119K Sell
24,447
-3,953
-14% -$30.3K ﹤0.01% 1329
2022
Q2 		$265K Buy
+28,400
New +$207K 0.01% 1173

Other funds holding IMPL

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's IMPL Position: Q4 2022 in Review

Ergoteles sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2022, closing a stake of 24,447 shares — an estimated $119K sold.

Ergoteles first reported a position in IMPL in Q2 2022 and held it in 2 quarters. The position peaked at $265K in Q2 2022. 35 funds tracked by Wall St. Rank hold IMPL as of Q4 2022.

  • Ergoteles reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 24,447 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2022, an estimated $119K.
  • Ergoteles first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Impel Pharmaceuticals Inc. Common Stock position peaked at $265K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.